These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1327 related articles for article (PubMed ID: 32568399)

  • 21. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.
    Saveanu R; Etkin A; Duchemin AM; Goldstein-Piekarski A; Gyurak A; Debattista C; Schatzberg AF; Sood S; Day CV; Palmer DM; Rekshan WR; Gordon E; Rush AJ; Williams LM
    J Psychiatr Res; 2015 Feb; 61():1-12. PubMed ID: 25586212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
    O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
    Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression.
    Zhdanov A; Atluri S; Wong W; Vaghei Y; Daskalakis ZJ; Blumberger DM; Frey BN; Giacobbe P; Lam RW; Milev R; Mueller DJ; Turecki G; Parikh SV; Rotzinger S; Soares CN; Brenner CA; Vila-Rodriguez F; McAndrews MP; Kleffner K; Alonso-Prieto E; Arnott SR; Foster JA; Strother SC; Uher R; Kennedy SH; Farzan F
    JAMA Netw Open; 2020 Jan; 3(1):e1918377. PubMed ID: 31899530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
    Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
    Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
    Braund TA; Palmer DM; Williams LM; Harris AWF
    Psychol Med; 2020 Apr; 50(6):1032-1042. PubMed ID: 31023398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
    Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH
    J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
    Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
    JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-trial prediction of treatment outcome in depression: a machine learning approach.
    Chekroud AM; Zotti RJ; Shehzad Z; Gueorguieva R; Johnson MK; Trivedi MH; Cannon TD; Krystal JH; Corlett PR
    Lancet Psychiatry; 2016 Mar; 3(3):243-50. PubMed ID: 26803397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.
    Williams LM; Debattista C; Duchemin AM; Schatzberg AF; Nemeroff CB
    Transl Psychiatry; 2016 May; 6(5):e799. PubMed ID: 27138798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
    Matrisciano F; Bonaccorso S; Ricciardi A; Scaccianoce S; Panaccione I; Wang L; Ruberto A; Tatarelli R; Nicoletti F; Girardi P; Shelton RC
    J Psychiatr Res; 2009 Jan; 43(3):247-54. PubMed ID: 18511076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
    Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
    J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
    Maller JJ; Broadhouse K; Rush AJ; Gordon E; Koslow S; Grieve SM
    Mol Psychiatry; 2018 Aug; 23(8):1737-1744. PubMed ID: 29133948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
    Arns M; Gordon E; Boutros NN
    Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.
    Webb CA; Trivedi MH; Cohen ZD; Dillon DG; Fournier JC; Goer F; Fava M; McGrath PJ; Weissman M; Parsey R; Adams P; Trombello JM; Cooper C; Deldin P; Oquendo MA; McInnis MG; Huys Q; Bruder G; Kurian BT; Jha M; DeRubeis RJ; Pizzagalli DA
    Psychol Med; 2019 May; 49(7):1118-1127. PubMed ID: 29962359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.